<DOC>
	<DOCNO>NCT01543100</DOCNO>
	<brief_summary>Blood circulate endothelial cell ( CEC ) microparticles ( MPs ) describe literature associate vascular failure dysfunction reflect neo-angiogenesis risk thrombosis , respectively . There number CEC healthy patient although significantly increase several cancer include myeloma . However , study explore date correlation CEC and/or circulate endothelial progenitor ( CEP ) MPs tumoral growth monoclonal gammopathy . On hand , study measure CEC CEP directly bone marrow . The investigator aim evaluate 2 original feature patient monoclonal gammopathy : monoclonal gammopathy undetermined signification ( MGUS ) myeloma . This preliminary multicentric study .</brief_summary>
	<brief_title>Prognostic Study Markers Angiogenesis Coagulability Patients With Monoclonal Gammopathy</brief_title>
	<detailed_description>Principal objective : Research correlation blood CEC MPs tumoral volume clinico-biological stag monoclonal gammopathy . Secondary objective : Research correlation bone marrow endothelial cell MPs , measure flow cytometry , tumoral volume clinico-biological stag monoclonal gammopathy . Principal analysis : Blood level CEC progenitor , soluble parameter angiogenesis coagulability , microparticles versus classical indicator tumoral growth monoclonal gammopathy ( beta2-microglobulin Ig peak ) . Secondary analysis : Bone marrow level endothelial cell progenitor , soluble parameter angiogenesis coagulability , microparticles versus classical indicator tumoral growth monoclonal gammopathy ( beta2-microglobulin Ig peak ) . Methodology : PACMoG interventional , prospective multicentric pilot study . Biologic parameter determine diagnosis monoclonal gammopathy . Results compare monoclonal gammopathy international stag clinical follow-up . Procedures : Specific test study realize : - Blood sample : 2 EDTA tube 1 tube without anticoagulant per include patient . - Bone marrow : 3 ml collect myelogram punction make diagnosis . In case , additional sampling performed . Specific analysis : - Specific biological assay blood bone marrow : - Endothelial progenitor cell level - Number cellular origin MPSs - Levels phospholipid-dependant coagulability - Soluble parameter angiogenesis ( VEGF , soluble CD146 , endostatin ) - Soluble parameter coagulability ( Levels thrombomodulin , tissue factor D-Dimer )</detailed_description>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<criteria>Patients monoclonal gammopathy either MGUS myeloma diagnosis 3 month first myeloma treatment chemotherapy and/or antiangiogenic drug . Patient 's age â‰¥ 18 year old , Patients sign specific consent study . Treatment chemotherapy and/or antiangiogenic drug inclusion Age &lt; 18 year old No specific consent study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>MGUS</keyword>
</DOC>